193 related articles for article (PubMed ID: 32535224)
21. Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy.
Verma M; Shimizu-Motohashi Y; Asakura Y; Ennen JP; Bosco J; Zhou Z; Fong GH; Josiah S; Keefe D; Asakura A
PLoS Genet; 2019 Dec; 15(12):e1008468. PubMed ID: 31877123
[TBL] [Abstract][Full Text] [Related]
22. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
[TBL] [Abstract][Full Text] [Related]
23. The golden retriever model of Duchenne muscular dystrophy.
Kornegay JN
Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
[TBL] [Abstract][Full Text] [Related]
24. Brain function in Duchenne muscular dystrophy.
Anderson JL; Head SI; Rae C; Morley JW
Brain; 2002 Jan; 125(Pt 1):4-13. PubMed ID: 11834588
[TBL] [Abstract][Full Text] [Related]
25. The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Duchenne Muscular Dystrophy Cardiomyopathy.
Soslow JH; Xu M; Slaughter JC; Crum K; Chew JD; Burnette WB; Su YR; Tomasek K; Parra DA; Markham LW
J Card Fail; 2019 Apr; 25(4):259-267. PubMed ID: 30763738
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial.
Flanigan KM; Voit T; Rosales XQ; Servais L; Kraus JE; Wardell C; Morgan A; Dorricott S; Nakielny J; Quarcoo N; Liefaard L; Drury T; Campion G; Wright P
Neuromuscul Disord; 2014 Jan; 24(1):16-24. PubMed ID: 24321374
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.
Miyatake S; Shimizu-Motohashi Y; Takeda S; Aoki Y
Drug Des Devel Ther; 2016; 10():2745-58. PubMed ID: 27621596
[TBL] [Abstract][Full Text] [Related]
28. Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy.
Nguyen HQ; Iskenderian A; Ehmann D; Jasper P; Zhang Z; Rong H; Welty D; Narayanan R
CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):342-352. PubMed ID: 32419339
[TBL] [Abstract][Full Text] [Related]
29. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
30. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic effect of camostat mesilate on Duchenne muscular dystrophy in mdx mice.
Sawada H; Nagahiro K; Kikukawa Y; Ban S; Kakefuda R; Shiomi T; Yokosawa H
Biol Pharm Bull; 2003 Jul; 26(7):1025-7. PubMed ID: 12843632
[TBL] [Abstract][Full Text] [Related]
32. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
33. Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.
Mok E; Letellier G; Cuisset JM; Denjean A; Gottrand F; Alberti C; Hankard R
PLoS One; 2009; 4(5):e5448. PubMed ID: 19421321
[TBL] [Abstract][Full Text] [Related]
34. Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise.
Lowe J; Kadakia FK; Zins JG; Haupt M; Peczkowski KK; Rastogi N; Floyd KT; Gomez-Sanchez EP; Gomez-Sanchez CE; Elnakish MT; Rafael-Fortney JA; Janssen PML
J Neuromuscul Dis; 2018; 5(3):295-306. PubMed ID: 30010143
[TBL] [Abstract][Full Text] [Related]
35. Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A
EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914
[TBL] [Abstract][Full Text] [Related]
36. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.
Muntoni F; Tejura B; Spinty S; Roper H; Hughes I; Layton G; Davies KE; Harriman S; Tinsley J
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):922-933. PubMed ID: 30650257
[TBL] [Abstract][Full Text] [Related]
37. Molecular hydrogen alleviates motor deficits and muscle degeneration in mdx mice.
Hasegawa S; Ito M; Fukami M; Hashimoto M; Hirayama M; Ohno K
Redox Rep; 2017 Jan; 22(1):26-34. PubMed ID: 26866650
[TBL] [Abstract][Full Text] [Related]
38. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
[TBL] [Abstract][Full Text] [Related]
39. Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin.
Albuquerque-Pontes GM; Casalechi HL; Tomazoni SS; Serra AJ; Ferreira CSB; Brito RBO; de Melo BL; Vanin AA; Monteiro KKDS; Dellê H; Frigo L; Marcos RL; de Carvalho PTC; Leal-Junior ECP
Lasers Med Sci; 2018 May; 33(4):755-764. PubMed ID: 29209866
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy.
Boursereau R; Abou-Samra M; Lecompte S; Noel L; Brichard SM
BMC Biol; 2018 Mar; 16(1):33. PubMed ID: 29558930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
